modified l3000-selleck-anticancer-compound-library  (Selleck Chemicals)

Journal: NPJ Precision Oncology

Article Title: Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancer

doi: 10.1038/s41698-024-00757-w

Figure Lengend Snippet: a ALK1510-c4 cells and ALK1510-c4 DTP cells were cultured with each of the 3114 compounds in an anticancer drug compound library ( n = 1). Antiproliferative effects on ALK1510-c4 DTP cells relative to ALK1510-c4 cells are plotted as ratios in an ascending order for each compound by evaluating cell viability of the respective cells. b Top ten compounds with antiproliferative effects on ALK1510-c4 DTP cells relative to ALK1510-c4 cells are tabulated. c Cell proliferation assay/cytostatic studies showing relative cell viability/difference in drug sensitivity of ALK1510-c4 cells and ALK1510-c4 DTP cells after treatment with dacomitinib, neratinib, AZ6102, G007-LK, LY2090314, and omecamtiv mecarbil; mean [SD] of n = 3 experiments, * P < 0.05 between ALK1510-c4 and ALK1510-c4 DTP ; Student’s t test).

Article Snippet: For compound library screening, anticancer compound library was obtained from TargetMol (Boston, MA, USA).

Techniques: Cell Culture, Drug discovery, Proliferation Assay